Top

International Urology and Nephrology

Published in:

01-11-2016 | Nephrology - Original Paper

Underlying renal insufficiency: the pivotal risk factor for Pneumocystis jirovecii pneumonia in immunosuppressed patients with non-transplant glomerular disease

Authors: Wen-Ling Ye, Nan Tang, Yu-Bing Wen, Hang Li, Min-Xi Li, Bin Du, Xue-Mei Li

Published in: International Urology and Nephrology | Issue 11/2016

Abstract

Purposes

Data on PCP in patients with glomerular disease are rare. The aim of this study was to assess the predictors of PCP development, the risk factors for mortality and the incidence of acute kidney injury (AKI) when high-dose trimethoprim–sulphamethoxazole (TMP-SMX) was used in patients with non-transplant glomerular disease.

Methods

Forty-seven patients with PCP, as confirmed by positive results for Pneumocystis jirovecii DNA or Pneumocystis jirovecii cysts tested by a methenamine silver stain between January 1, 2003, and December 30, 2012, were retrospectively investigated. The baseline characteristics of glomerular disease, clinical findings of PCP and renal parameters after treatment were collected. Predictors for PCP development and risk factors for mortality were determined using a multivariate logistic regression analysis.

Results

All PCP patients exclusively received immunosuppressants. Baseline renal insufficiency [estimated glomerular filtration rate (eGFR) <60 mL/min·1.73 m²] was present in 87.23 % of patients. The overall mortality rate was 29.79 %. A pulmonary coinfection and the need for mechanical ventilation were independently associated with PCP mortality. A lower eGFR, lower serum albumin level and a higher percentage of global glomerulosclerosis were independent predictors of PCP in patients with IgA nephropathy receiving immunosuppressants. AKI occurred in 60.47 % of patients who received TMP-SMX. After treatment cessation, 93.75 % of surviving patients showed a recovery of renal function to baseline values.

Conclusions

PCP is a fatal complication in patients with glomerular disease, and the use of immunosuppressants may be a basic risk factor for this infection. Underlying renal insufficiency and high renal pathology chronicity are the key risk factors for PCP in IgA nephropathy. TMP-SMX therapy remains an ideal choice because of high treatment response and frequently reversible kidney injury.

Thomas CF Jr, Limper AH (2004) Pneumocystis pneumonia. N Engl J Med 350:2487–2498CrossRefPubMed

Matsumura Y, Shindo Y, Iinuma Y, Yamamoto M, Shirano M et al (2011) Clinical characteristics of Pneumocystis pneumonia in non-HIV patients and prognostic factors including microbiological genotypes. BMC Infect Dis 11:76–84CrossRefPubMedPubMedCentral

Okafor PN, Nunes DP, Farraye FA (2013) Pneumocystis jiroveci pneumonia in inflammatory bowel disease: when should prophylaxis be considered? Inflam Bowel Dis 19(8):1764–1771CrossRef

Wang EH, Partovi N, Levy RD et al (2012) Pneumocystis pneumonia in solid organ transplant recipients: not yet an infection of the past. Transpl Infect Dis 14(5):519–525CrossRefPubMed

Guo F, Chen Y, Yang SL et al (2014) Pneumocystis pneumonia in HIV-infected and immunocompromised non-HIV infected patients: a retrospective study of two centers in China. PLoS ONE 9(7):e101943CrossRefPubMedPubMedCentral

Fillatre P, Decaux O, Jouneau S et al (2014) Incidence of Pneumocystis jiroveci pneumonia among groups at risk in HIV-negative patients. Am J Med 127(12):1242.e11–1242.e17CrossRef

Roblot F, Le Moal G, Kauffmann-Lacroix C et al (2014) Pneumocystis jirovecii pneumonia in HIV-negative patients: a prospective study with focus on immunosuppressive drugs and markers of immune impairment. Scand J Infect Dis 46(3):210–214CrossRefPubMed

Zhang L, Wang F, Wang L et al (2012) Prevalence of chronic kidney disease in China: a cross-sectional survey. Lancet 379(9818):815–822CrossRefPubMed

Lv J, Zhang H, Cui Z et al (2008) Delayed severe pneumonia in mycophenolate mofetil-treated patients with IgA nephropathy. Nephrol Dial Transpl 23(9):2868–2872CrossRef

10.

Yang CY, Yang AH, Yang WC, Lin CC (2012) Risk factors for Pneumocystis jiroveci pneumonia in glomerulonephritis patients receiving immunosuppressants. Intern Med 51:2869–2875CrossRefPubMed

11.

Tasaka S, Tokuda H (2012) Pneumocystis jirovecii pneumonia in non-HIV-infected patients in the era of novel immunosuppressive therapies. J Infect Chemother 18(6):793–806CrossRefPubMed

12.

Cruz DN, Bagshaw SM, Ronco C, Ricci Z (2010) Acute kidney injury: classification and staging. Contrib Nephrol 164:24–32CrossRefPubMed

13.

Madero M, Sarnak MJ (2011) Creatinine-based formulae for estimating glomerular filtration rate: is it time to change to chronic kidney disease epidemiology collaboration equation? Curr Opin Nephrol Hypertens 20(6):622–630CrossRefPubMed

14.

Enomoto T, Azuma A, Kohno A et al (2010) Differences in the clinical characteristics of Pneumocystis jirovecii pneumonia in immunocompromized patients with and without HIV infection. Respirology 15:126–131CrossRefPubMed

15.

Mansharamani NG, Garland R, Delaney D, Koziel H (2000) Management and outcome patterns for adult Pneumocystis carinii pneumonia, 1985 to 1995: comparison of HIV-associated cases to other immunocompromised states. Chest 118(3):704–711CrossRefPubMed

16.

Mori S, Sugimoto M (2012) Pneumocystis jirovecii infection: an emerging threat to patients with rheumatoid arthritis. Rheumatology (Oxford) 51(12):2120–2130CrossRef

17.

Plakke MJ, Jalota L, Lloyd BJ (2013) Pneumocystis pneumonia in a non-HIV patient on chronic corticosteroid therapy: a question of prophylaxis. BMJ Case Rep. doi:10.1136/bcr-2012-007912

18.

Yale SH, Limper AH (1996) Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illnesses and prior corticosteroid therapy. Mayo Clin Proc 71:5–13CrossRefPubMed

19.

GripaldoR LippmannML (2012) Pneumocystis pneumonia in HIV-negative patients: a review of the literature. Clin Pulm Med 19:5–13CrossRef

20.

Reid AB, Chen SC, Worth LJ (2011) Pneumocystis jirovecii pneumonia in non-HIV-infected patients: new risks and diagnostic tools. Curr Opin Infect Dis 24:534–544CrossRefPubMed

21.

Girndt M, Sester U, Sester M, Kaul H, Kohler H (1999) Impaired cellular immunity in patients with end-stage renal failure. Nephrol Dial Transpl 14:2807–2810CrossRef

22.

Girndt M, Sester M, Sester U, Kaul H, Kohler H (2001) Molecular aspects of T- and B-cell function in uremia. Kidney Int 78:S206–S211CrossRef

23.

Vaziri ND, Pahl MV, Crum A, Norris K (2012) Effect of uremia on structure and function of immune system. J Ren Nutr 22(1):149–156CrossRefPubMedPubMedCentral

24.

Yoon J, Gollapudi S, Pahl M, Vaziri N (2006) Naïve and central memory T-cell lymphopenia in end-stage renal disease. Kidney Int 70:371–376CrossRefPubMed

25.

Massry S, Smogorzewski M (2001) Dysfunction of polymorphonuclear leukocytes in uremia: role of parathyroid hormone. Kidney Int 78:S195–S196CrossRef

26.

Smogorzewski M, Massry SG (2001) Defects in B-cell function and metabolism in uremia: role of parathyroid hormone. Kidney Int 78:S186–S189CrossRef

27.

Eitner F, Hauser IA, Rettkowski O et al (2011) Risk factors for Pneumocystis jiroveci pneumonia (PCP) in renal transplant recipients. Nephrol Dial Transpl 26:2013–2017CrossRef

28.

Roblot F, Godet C, Le Moal G et al (2002) Analysis of underlying diseases and prognosis factors associated with Pneumocystis carinii pneumonia in immunocompromised HIV-negative patients. Eur J Clin Microbiol Infect Dis 21(7):523–531CrossRefPubMed

29.

Festic E, Gajic O, Limper AH, Aksamit TR (2005) Acute respiratory failure due to Pneumocystis pneumonia in patients without human immunodeficiency virus infection: outcome and associated features. Chest 128:573–579CrossRefPubMed

30.

Fillatre P, Chevrier S, Revest M et al (2013) Human herpes virus co-infection is associated with mortality in HIV-negative patients with Pneumocystis jirovecii pneumonia. Eur J Clin Microbiol Infect Dis 32(2):189–194CrossRefPubMed

31.

Fraser TN, Avellaneda AA, Graviss EA, Musher DM (2012) Acute kidney injury associated with trimethoprim/sulfamethoxazole. J Antimicrob Chemother 67(5):1271–1277CrossRefPubMed

32.

Klinker H, Langmann P, Zilly M, Richter E (1998) Drug monitoring during the treatment of AIDS-associated Pneumocystis carinii pneumonia with trimethoprim-sulfamethoxazole. J Clin Pharm Ther 23(2):149–154CrossRefPubMed

33.

Stevens RC, Laizure SC, Williams CL, Stein DS (1991) Pharmacokinetics and adverse effects of 20-mg/kg/day trimethoprim and 100-mg/kg/day sulfamethoxazole in healthy adult subjects. Antimicrob Agents Chemother 35(9):1884–1890CrossRefPubMedPubMedCentral

34.

Smith EJ, Light JA, Filo RS, Yum MN (1980) Interstitial nephritis caused by trimethoprim-sulfamethoxazole in renal transplant recipients. JAMA 244:360–361CrossRefPubMed

35.

Rudra T, Webb DB, Evans AG (1989) Acute tubular necrosis following co-trimoxazole therapy. Nephron 53:85–86CrossRefPubMed

36.

Kaplan JE, Benson C, Holmes KK et al (2009) Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recommend Rep 58(4):1–207

37.

Sepkowitz KA (1996) Pneumocystis carinii pneumonia without acquired immunodeficiency syndrome: who should receive prophylaxis? Mayo Clin Proc 71:102–103CrossRefPubMed

38.

Mansharamani NG, Balachandran D, Vernovsky I, Garland R, Koziel H (2000) Peripheral Blood CD4 1 T-Lymphocyte counts during Pneumocystis carinii pneumonia in immunocompromised patients without HIV infection. Chest 118:712–720CrossRefPubMed

Title: Underlying renal insufficiency: the pivotal risk factor for Pneumocystis jirovecii pneumonia in immunosuppressed patients with non-transplant glomerular disease
Authors: Wen-Ling Ye
Nan Tang
Yu-Bing Wen
Hang Li
Min-Xi Li
Bin Du
Xue-Mei Li
Publication date: 01-11-2016
Publisher: Springer Netherlands
Published in: International Urology and Nephrology / Issue 11/2016
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI: https://doi.org/10.1007/s11255-016-1324-x

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Underlying renal insufficiency: the pivotal risk factor for Pneumocystis jirovecii pneumonia in immunosuppressed patients with non-transplant glomerular disease

Abstract

Purposes

Methods

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purposes

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 11/2016

Bone remodeling markers as lithogenic risk factors in patients with osteopenia–osteoporosis

Congenital lymphovascular malformations with urological symptoms: a report of two cases and review of the literature

Renal functional outcomes after robotic multiplex partial nephrectomy: the National Cancer Institute experience with robotic partial nephrectomy for 3 or more tumors in a single kidney

Survival following laparoscopic adrenalectomy for solitary metastasis of lung cancer

Sunitinib in metastatic renal cell carcinoma (mRCC): a developing country experience. Do our patients behave differently than the Western patients?

Review of “The Nurse Practitioner in Urology”

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page